Plasma from patients who have recovered from SARS-CoV-2 infection (convalescent plasma) contains antibodies that can bind to and neutralise the virus. Infusion of convalescent plasma containing high concentrations of neutralising antibody may theoretically accelerate clearance of the virus and clinical improvement. Although convalescent plasma has been widely used in patients admitted to hospital with COVID-19, data from randomised controlled trials in this patient group have, until recently, been limited. This webinar provides evidence from randomised controlled trials of the safety and efficacy of convalescent plasma in patients hospitalised for COVID-19. Join an extraordinary panel of leading international experts, including Professor Peter Horby talking about the RECOVERY Trial, to hear the latest research and have the opportunity to ask questions.